PUBBLICATO ARTICOLO SCIENTIFICO SU UTILIZZO DELLA CANNABIS NEI PAZIENTI AFFETTI DA FIBROMIALGIA

È GIUSTO INFORMARE

Fibromialgia (FM)  

COMPLIMENTI CONGRATULAZIONI AD ANTONIO GIARDINA E TUTTA LA EQUIPE 

Con grande soddisfazione personale e del mio gruppo di lavoro è stato pubblicato, su un importante rivista internazionale, un articolo scientifico, relativo all’utilizzo della Cannabis Terapeutica nei pazienti affetti da Fibromialgia.

PUBBLICATO ARTICOLO SCIENTIFICO SU UTILIZZO DELLA CANNABIS NEI PAZIENTI AFFETTI DA FIBROMIALGIA 

Il lavoro è stato portato a termine in sinergia con il Prof. Luigi Milella del Dipartimento di Scienze dell’Università degli Studi della Basilicata e della sua equipe che ringrazio per la disponibilità e professionalità 

Quando le cose funzionano in Regione Basilicata riusciamo anche ad essere attrattivi nel mondo scientifico internazionale

AOR SAN CARLO

Federdolore

Fondazione ISAL

Fibromialgia News by CFU-Italia odv

CFU-Italia: il nostro gruppo

📌 https://www.mdpi.com/2077-0383/13/14/4088/pdf

#terapiadeldolore

*^*

Article

Is a Low Dosage of Medical Cannabis Effective for Treating Pain Related to Fibromyalgia? A Pilot Study and Systematic Review

Antonio Giardina 1, Rocco Palmieri 1, Maria Ponticelli 23*, Carlo Antonelli 1, Vittorio Carlucci 2, Monica Colangelo 1, Nadia Benedetto 3, Aldo Di Fazio * and Luigi Milella 2*

1.   Pain Therapy Unit, San Carlo Hospital, via Potito Petrone, 85100 Potenza, Italy; antonio.giardina@ospedalesancarlo.it (A.G.); rocco.palmieri@ospedalesancarlo.it (R.P.);
   carlo.antonelli@ospedalesancarlo.it (C.A.); monica.colangelo@ospedalesancarlo.it (M.C.)
2.   Department of Science, University of Basilicata, Via dell’Ateneo Lucano 10, 85100 Potenza, Italy;
   vittorio.carlucci@unibas.it (V.C.); nadia.benedetto@unibas.it (N.B.)
   Department of Biochemical Pharmacology & Drug Design, Institute of Molecular Biology

“Roumen Tsanev”, Bulgarian Academy of Sciences (BAS), Acad. G. Bonchev Str., bl. 21, 1113 Sofia, Bulgaria + Regional Complex Intercompany Institute of Legal Medicine, 85100 Potenza, Italy;

aldo.difazio@ospedalesancarlo.it

* Correspondence: maria.ponticelli@unibas.it (M.P.); luigi.milella@unibas.it (L.M.)

Abstract: Background and Objectives: Fibromyalgia is a multifaceted and frequently misunderstood chronic pain disease marked by widespread musculoskeletal pain and cognitive/somatic dys-function. This trial aims to contribute to the existing knowledge on treating fibromyalgia (FM) with medical cannabis (Cannabis sativa L.) and explore a safer and more effective cannabis administration method. The goal is to provide evidence-based findings that can guide alternative treatment options for FM patients by assessing a pilot study. Materials and Methods: The trial was performed at the pain therapy unit of the San Carlo Hospital (Potenza, Italy) by administrating to 30 FM patients 100 mg/day of Bedrocan® as a decoction. The Numerical Rating Scale (NRS) and SF-12 short-form health questionnaire were used to evaluate pain intensity and the quality of life at the beginning of the study and the 6th-month follow-up. A systematic review of all clinical studies investigating the use of cannabis to reduce FM was also undertaken to place this study in the context of the existing evidence base. Results: Pain intensity evaluated with the NRS lowered from a median of 8[95% CI

7.66-8.54] at a baseline to a median of 4 (95% Cl 3.28-4.79) after 6 months of follow-up (p-value <

0.001; t-Test). Similarly, significant physical and mental state improvement, evaluated with the SF-12 questionnaire, was found in 96.67% and 82.33% of patients, respectively (95% CI 44.11-51.13 for the physical state, and 53.48-58.69 for mental state assessed after the 6th-month follow-up; p-value < 0.001; t-Test). The systematic analysis of the literature identified 10 clinical trials concerning the treatment of fibromyalgia with cannabis. Conclusions: Considering results from the present pilot study and systematic review, it is possible to assume that medical cannabis may be considered an alternative therapy for FM patients who do not respond to conventional pharmacological therapy.

Keywords: medical cannabis; Bedrocan®; fibromyalgia; pilot study; systematic review

1. Introduction

Fibromyalgia (FM) is a term introduced in the early 1970s denoting a multifaceted and challenging clinical condition that transcends conventional medical classifications.

FM definition has been revised significantly over the years, reflecting the evolving understanding of the condition. Initially considered mainly as a rheumatic disorder, it is now acknowledged as a pain processing disorder and sensitization of the central nervous system [1]. FM is, indeed, one of the most common causes of persistent chronic

Citation: Giardina, A.; Palmieri, R.;

Ponticelli, M.; Antonelli, C.;

Carlucci, V.; Colangelo, M.;

Benedetto, N.; Di Fazio, A.;

Milella, L. Is a Low Dosage of Medical Cannabis Effective for

Treating Pain Related to Fibromyalgia? A Pilot Study and Systematic Review. J. Clin. Med.

2024, 13, 4088. https://doi.org/

10.3390/jcm13144088

Academic Editor: Stephane Mouly

Received: 11 June 2024

Revised: 5 July 2024

Accepted: 8 July 2024

Published: 12 July 2024

Copyright: © 2024 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
	distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license
	(https://creativecommons.org/license
s/by/4.0/)-

TRADUZIONE DI CORTESIA

Articolo

Un basso dosaggio di cannabis terapeutica è efficace nel trattamento del dolore legato alla fibromialgia?

Uno studio pilota e una revisione sistematica

Antonio Giardina 1, Rocco Palmieri 1, Maria Ponticelli 23*, Carlo Antonelli 1, Vittorio Carlucci 2, Monica Colangelo 1, Nadia Benedetto 3, Aldo Di Fazio * e Luigi Milella 2*

1. Introduzione

Fibromialgia (FM) è un termine introdotto all’inizio degli anni ’70 che denota una condizione clinica complessa e complessa che trascende le classificazioni mediche convenzionali.

La definizione di FM è stata rivista in modo significativo nel corso degli anni, riflettendo l’evoluzione della comprensione della condizione. Inizialmente considerata principalmente come una malattia reumatica, oggi è riconosciuta come un disturbo dell’elaborazione del dolore e della sensibilizzazione del sistema nervoso centrale [1]. La FM è, infatti, una delle cause più comuni di cronica persistente